Replies to post #229887 on NorthWest Biotherapeutics Inc (NWBO)

[JTORENCE]

radon welcome aboard. Like your style with Photonic5. Keep on his ass ..lol

[abeta]

radonculous

I Swear to God - in all the time I've been here - YEARS

I only recall him posting ------ ONCE -------

A better way (with respect) to punish him is to force him to
post multiple times a day ...... THAT would teach him a lesson

just trying to help ......

You know - I (almost) don't remember his name .....

regards

[photonic5]

Young cancer doctors = egomaniacs. Must teach that in residency these days. Glad you studied up on your immunotherapy. Now go pass your boards.

[BioInfo]

Welcome aboard. Long since 2009

[Survivor2012]

radon, welcome aboard -- buckle your seat belt!

[H2R]

You may have a great timing with your investment. Most longs have been in for years.

Wishing you radonculous riches with this promising company!

Best of luck to Patients, NWBO, and Longs!

[Lorie3168]

Welcome radonculous. I guess your buddy got you buying at the perfect time. Many of us here have not been so lucky. However many of us VERY LONGS, have been fortunate to accumulate multitudes of shares over the years!! And over the years some people, like me, have been lucky enough to follow some of the very smart people here, who have helped me to learn WHY IM NOT SELLING YET!!

[Evaluate]

Hi Radonculous. you wrote:

In addition to being a physician, I also have an MPH in epidemiology and have a lot of experience with clinical trials, study design, statistics, etc.
Feel free to ask me any questions.

Since you offered ...
What are some of your thoughts in regards to finalizing the SAP's?
Do you feel enough time has gone by that NWBO may have already submitted these to the 4 Regulatory Agencies?
Do you think that NWBO may have already received revised SAP approval from any/all 4 RAs?
What main revisions do you believe NWBO might be incorporating in these revised SAPs?
How to statistically interpret PFS events & pseudoprogression?
Surgery with/without dyes (5 ALA)?
White blood cells counts?
Other factors?
What is your current expected timeframe for topline/data lock? From the PR it appears this will not be announced at ASCO ... are you thinking perhaps within weeks, or perhaps towards year-end?
Statistics: which of the trial results do you believe might have improved compared to their most recent blinded results disclosed?
Do you think that Primary Endpoint (PFS) might still come through OK? Or that the long tail of OS will need to "save the day/trial"?
Once unblinded, where do you figure the OS results might wind up for:
Treatment Group (early DCVax)?
Placebo Group (no DCVax versus Late DCVax)?

Assuming approval of DCVax-L, which country/RA do you believe might grant approval first?

[xoma4578]

Radon...welcome on board.

Stay long and be richly rewarded.

[alphapuppy]

Welcome to the board RadOnc!!

Just want him to pick your brain about what your take is on the statistical models that have been presented on this board and the statistics that have been presented by the company. It seems to me that these all point towards a positive trial results.

Are we missing anything?

[survivor1x]

Welcome to the board.

Can you tell me your thoughts on this and pspd vs. Pd differentiation?

https://www.pnas.org/content/114/38/10220

The case studies of the first three patients are outlined below. Patient A received tumor lysate-pulsed DCVax before imaging and then PD-1 antibody blockade during the interval between the first and second [18F]-CFA PET scans. The posttreatment [18F]-CFA PET scan demonstrated elevated uptake in several peripheral lymph nodes and in the tumor (Fig. 5A) compared with the first scan done 3 wk earlier, in agreement with the results of the murine studies. Advanced MRI revealed an increase in the tumor’s subtraction map (T1+C – T1). MRI with apparent diffusion coefficient (ADC) maps and cerebral blood volume (CBV) perfusion-weighted MRI suggested an almost 300% increase in immune cells in the tumor microenvironment, with the tumor volume remaining fairly constant (Fig. 6A).